News Sentiment

AGIO sentiment intelligence

Agios Pharm news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 41.23 Week of 10 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+9.7% over one week, +40.0% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued?

Market Reaction

Price moving ahead of tone

71/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 9.7% Price confirming higher
Trend fit Trend active 40.0% over four weeks
Fair value 23.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 27
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 6
TradingView 5
Investing.com 4
Simply Wall Street 3
The Motley Fool 2
Moomoo 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 11
Analyst action 4
Regulatory and legal 2
Guidance 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-49 of 49
Stock Titan Direct company coverage

Agios (NASDAQ: AGIO) CMO nets shares after RSU vesting and tax sale

Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, reported a routine equity transaction where 8,375 restricted stock units vested and converted into common shares. To cover tax obligations, 4,007 shares were sold at $37.56 each under a pre-arranged 10b5-1 plan. Followi

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

D. E. Shaw reports 3.03M-share stake in Agios (AGIO)

D. E. Shaw & Co., L.P. and David E. Shaw have reported a 5.1% stake in Agios Pharmaceuticals (AGIO), totaling 3,034,031 shares, through a Schedule 13G SEC filing. The filing indicates shared voting power over 2,863,931 shares and shared dispositive power over all 3,034,031 shares

Tone
Neutral 50/100
Event
Deals and strategy
Published
02 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

AGIO (NASDAQ: AGIO) affiliate notifies plan to offer 4,007 shares via broker

An affiliate of Agios Pharmaceuticals (NASDAQ: AGIO) has filed a Form 144, indicating a plan to offer 4,007 shares of common stock. These shares are associated with the vesting of restricted stock units on July 1, 2026, and will be sold through Morgan Stanley Smith Barney LLC. Th

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 19:41
Source
Stock Titan
Simply Wall Street Direct company coverage

How Agios Pharmaceuticals' Shift Into Russell Growth Indices Will Impact Agios Pharmaceuticals (AGIO) Investors

Agios Pharmaceuticals (AGIO) has been added to several Russell growth benchmarks, including the Russell 2000 Growth, indicating an increasing perception of the company as a growth-oriented biotech. This reclassification could attract more growth-focused institutional investors an

Tone
Positive 62/100
Event
Market update
Published
01 Jul 2026 08:41
Source
Simply Wall Street